FDA clears Travere’s FILSPARI for expanded use in rare kidney disease

Novartis expands global push to close life-saving gaps in heart disease & cancer care by 2030

Each program will rely on partnerships between Novartis teams and local networks—including health authorities, community organizations and private sector groups

Thailand and GHIT Fund join forces to tackle infectious diseases

The collaboration promises expanded funding for Thai universities, research institutes, companies, and global research partners working in Thailand

World Health Day: Late diagnosis, rising lifestyle diseases put young India at risk

Sharp increase in diabetes, hypertension and fatty liver in 30–50 age group

Practo reports surge in lifestyle disease awareness within Tier 2 cities, led by metabolic health searches

Searches for diabetes, heart conditions, and metabolism-related risks are rising sharply, with Tier 2 cities outpacing metros in specialist consultations

Innovent Biologics’ OLN324 shows breakthrough results in vision disease study

The JADE trial enrolled 164 U.S. patients who initially received three monthly doses of OLN324 or faricimab, followed by 12 weeks off treatment with retreatment allowed only if disease recurred

Bayer plans to offer Eylea 2mg at lower cost in India for benefit of retinal disease patients

Eylea 2mg (intravitreal aflibercept injection) is an anti-VEGF therapy that blocks a protein responsible for abnormal blood vessel growth and leakage in the retina

Biogen to buy Apellis Pharmaceuticals for $5.6B in rare disease and immunology push

The acquisition brings two commercialized, differentiated medicines—EMPAVELI and SYFOVRE —to Biogen’s growth portfolio

Investigational therapy efzimfotase alfa shows promising Phase III results in rare bone disease

Efzimfotase alfa is an investigational enzyme replacement therapy designed to reduce injection volume

AbbVie stakes claim to redefine skin disease treatment at Global Dermatology Summit

Beyond clinical trials, real-world evidence is adding weight to AbbVie’s claims